Apt Software Avenues Private Limited, Unit G301 & 302, Block DC, City Centre, Salt Lake, Kolkata, India
*Corresponding author: pratimc@aptsoftware.com
Online published on 19 February, 2018.
Malaria is a serious issue for its negative impact on the community and the increasing resistance to drugs. Hence the treatment of malaria is a great challenge for the community. While studying the complex interaction of molecules between host and the malarial parasite from the point of entry and the subsequent invasion within the RBC, it seemed that there might be a certain crucial juncture where the process can be intervened. We have focussed on these interaction pathways and various antagonistic drugs that act in these pathways to deal with malarial infection. CQ and Art are the frequently used drugs worldwide but, now-a-days the event of they becoming resistant have also been reported. Mutations in Digestive Vacuole Membrane Transporters make CQ ineffective whereas, the reason behind the Art resistant is the mutation in the K13 gene. The K13 gene product binds with the Nrf2, a transcriptional factor of anti-oxidants producing gene. This binding makes the Nrf2 ineffective causing the death of the parasites under stressed condition. Our aim of the study is to find a way out to inactivate Nrf2 in order to increase the Art efficiency.
Malaria, Chloroquine, Artemisinin, PfPI3K, RBC